Computational Biology Market Size & Share, by Product (Software, Services, Infrastructure); Application; End user; Technology; Service; Type - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2026-2035

  • Report ID: 3921
  • Published Date: Aug 14, 2025
  • Report Format: PDF, PPT

Computational Biology Market Outlook:

Computational Biology Market size was valued at USD 7.2 billion in 2025 and is projected to reach USD 22.8 billion by the end of 2035, rising at a CAGR of 13.7% during the forecast period, from, 2026-2035. In 2026, the industry size of computational biology is evaluated at USD 7.8 billion.

The aspect of conducting modern research for biology and healthcare utilizes a huge amount of biological information. This has ensured innovation in disease understanding, personalized medicine, and drug discovery, which is effectively uplifting the computational biology market globally. Therefore, to conduct research, various administrative bodies and governmental organizations have come forward to initiate funds and investments. For instance, as per an article published by Oxford Academic in September 2024, the Agency for Healthcare Research and Quality (AHRQ) funded 28 grants, which have aimed to increase the knowledge base to understand patients’ demands. Thus, the aspect of innovation in research through generous investments is positively impacting the overall market globally.

Furthermore, to ensure a smooth processing of computational imaging in the computational biology market, the incorporation of tools is essential. These include optical, photo, and film equipment that are readily utilized in computational imaging that integrate optical techniques for automating biological samples, extracting increased information, and augmenting image quality. In this regard, the 2023 OEC report has pointed out the export and import details of these tools, with the global trade valuation of USD 655 billion, a share of 2.9%, and product complexity of 0.9. Besides, the U.S. is both the top exporter and importer, with USD 106 billion and USD 117 billion, thereby denoting a huge opportunity for the market.

Computational Biology Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Uprising in artificial intelligence: The existence of AI has been transforming conventional drug discovery, as well as developmental models by implementing algorithms, computational power, and data. As stated in the February 2025 Journal of Pharmaceutical Analysis report, Heal-X, as of 2021, deliberately used AI to recognize the latest utilization of the HLX-0201 drug. This has been suitable for aiding fragile X syndrome and advancing the project to Phase II clinical trials within 1.6 years. This is a huge driver for augmenting the success, accuracy, and efficiency of drug development, which is boosting the market internationally.
     
  • Revolution in genetic engineering: This field is currently witnessing revolutionary advancements, which are fueled by technologies, including CRISPR-Cas9, denoting a positive impact on the market. Besides, through the adoption of gene technology, scientists can positively influence the reproductive health of particular genes. As per an article published by Carnegie Endowment for International Peace in October 2024, the staggering cost for this procedure was USD 2.7 billion, particularly for the human genome. At present, this can be conducted within a day, and the overall expense is USD 600, thereby denoting the cost-effectiveness aspect.
     
  • Innovation in cardiovascular disease research: Biomarkers and conventional risk factors of CVD have been mainly undergoing research through clinical observations. According to the September 2024 NPJ article, this disease has been one of the leading causes of death, accounting for 50% across high-income nations and 28% in low-income nations. In addition, for the past 6 years, CVD incidence has also been the main reason for poor life expectancy and health among 369 other disorders. This has created a huge opportunity for the market to identify potential biomarkers, along with analyzing model biological systems and large datasets.

Efficiency Boost in Science Through Computational Biology

In-disciplinary Team Science Support to Accelerate Biological Discoveries

Components

Biology

Computer Science

Biology Silo

100%

-

Biological-Focused Research Parasitism

95%

5%

Data Generation Focused Collaboration

90%

10%

Data Science Focused Collaboration

15%

85%

Computationally-Focused Research Parasitism

10%

90%

Computational Silo

-

100%

Source: NLM, October 2021

Computational Biology Market Drives Pathogen Genomics Investment

Investment and Cost Cases for Pathogen Genomics

Component

Benefits

Enhanced meningococcal disease control efforts in Africa

Cost savings up to USD 80

Reduction in medical expenses and productivity loss

USD 507 million

Improved recall of tainted food products

USD 37 million

Disease burden

100,000 per individual

Source: Cell Genomics, March 2025

Challenges

  • Increased treatment expenses and limited insurance services: The presence of substantial expenses linked with solutions in the market has created huge barriers for adoption, especially across fragmented healthcare systems. For instance, Medicaid programs and private insurers have initiated independent coverage strategies to ensure reimbursement for innovative computational diagnostics. Besides, the price points for wide-ranging genomic profiling have made these services unavailable for the majority of patients in the absence of insurance coverage, thus causing a hindrance in the market’s development internationally.
     
  • Administrative delay in key economies: The international patchwork for administrative demands for tools in the market has developed challenges for market entry. Each high-income market has created its clearance framework for AI-based diagnostics, along with bioinformatics software, frequently with less harmonization between nations. For instance, Europe’s In Vitro Diagnostic Regulation (IVDR) has created identical bottlenecks with small-scale organizations that are struggling to meet strict clinical needs. Therefore, these delays comprise extremely severe consequences, thus causing a negative impact on the market.

Computational Biology Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Year

2026-2035

CAGR

13.7%

Base Year Market Size (2025)

USD 7.2 billion

Forecast Year Market Size (2035)

USD 22.8 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)

Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Computational Biology Market Segmentation:

Product Segment Analysis

Based on the product, the software segment in the computational biology market is projected to garner the highest share of 42.7% by the end of 2035. The segment’s growth is highly fueled by a surge in the demand for bioinformatic tools and AI-based drug discovery platforms. In this regard, notable players, such as Dassault BIOVIA and Schrödinger, are deliberately leading with cloud-based analytical solutions, as well as molecular modeling, which tends to diminish drug development timelines. Besides, open source tools, including Bioconductor, and commercial suites, such as NDAnexus, both effectively cater to diversified demands, ranging from genomics to precision medicine, thus are suitable for the segment’s upliftment.

Application Segment Analysis

Based on the application, the precision medicine segment in the computational biology market is expected to hold the second-highest share of 29.5% during the forecast timeline. According to an article published by NLM in December 2024, a clinical study was conducted by collecting 5,322 reports from the U.S. FDA reporting system, denoting patients who experienced more than 40% hospitalization, and death in more than 10% of cases. Therefore, to keep control of this, precision medicine exists to revolutionize healthcare through molecular technologies, such as microbiomics, metabolomics, proteomics, transcriptomics, and genomics. Additionally, by analyzing biological data researchers are able to recognize genetic markers, develop personalized treatment, and predict disease risk.

End user Segment Analysis

Based on the end user, the pharmaceutical companies segment in the market is predicted to hold the third-highest share of 25.8% during the forecast period. These companies have implemented AI to optimize the efficiency of their respective drug candidates. As per the November 2022 NLM article, these companies are focusing on drug discovery, clinical testing, and approval for production. This has been possible through target identification, lead discovery and optimization, and preclinical testing, accounting for USD 600 million to USD 800 million within 7 to 10 years. Besides, Phases I, II, and III account for USD 1.2 billion to USD 1.4 billion, thus suitable for the segment’s growth.

Our in-depth analysis of the computational biology market includes the following segments:

Segment

Subsegments

Product

  • Software
    • AI/ML Platforms
    • Bioinformatics Tools
  • Services
    • Cloud Analytics
    • CROs
  • Infrastructure
    • HPC
    • Cloud Storage

Application

  • Precision Medicine
  • Drug Discovery & Development
  • Genomics & Proteomics

End user

  • Pharmaceutical Companies
  • Academic & Research Institutes
  • CROs & Diagnostic Labs

Technology

  • Next-Gen Sequencing (NGS) Analytics
  • Molecular Modeling
  • Structural Bioinformatics

Service

  • Databases
  • Infrastructure & Hardware
    • Cloud Analytics
    • CROs
  • Software Platform
    • AI/ML Platforms
    • Bioinformatics Tools

Type

  • Cellular & Biologic Simulation
    • Computational Genomics
    • Computational Proteomics
    • Pharmacogenomics
    • Others
  • Disease Modeling & Simulation
    • Drug Discovery
    • Drug Development
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.


Computational Biology Market - Regional Analysis

North America Market Insights

North America in the computational biology market is projected to hold the largest share of 42.2% by the end of 2035. The market’s growth in the region is highly propelled, owing to its demand across research and academic facilities for different drug discovery and development, along with the presence of a strong U.S. biotechnology and biopharmaceutical sector. As per the April 2022 NLM article, the U.S. FDA increased its approval track for personalized medicine in the region from 21% to 39% within the past 5 years. In addition, regional strategies have been unveiled to provide back-up for personalized medicine through translation and research, along with the provision of government investment of USD 4 billion, thereby suitable for the market’s growth.

The market in the U.S. is also significantly growing, owing to generous funding allocation. According to an article published by the U.S. Department of Energy in August 2023, the organization declared the provision of USD 4.7 million for 5 latest research projects, pertaining to computational biology. The purpose was to assist these projects in developing cutting-edge analytical and software tools and administer the increased quantities of genomics, originating from biological systems and microbes. In addition, the Biological and Environmental Research (BER) Genomic Science program utilizes the genome, which has effectively enabled approaches to recognize basic principles to drive biological systems in the country.

The market in Canada is also growing, owing to contributions initiated by the government through budget provision, particularly for genomics strategy. In this regard, as per the February 2025 Heath Canada report, there has been a commitment of more than USD 1.6 billion for more than 20 years through Genome Canada's funding, especially for large-scale applied and translational genomics. Besides, to support the country’s robust support for genomics translation and research, the government of Canada has allocated USD 175.1 million for more than 7 years to effectively back the regional Genomics Strategy, thus suitable for boosting the market in the country.

Disease/Use

Trade Name

Manufacturer

Acute Myeloid Leukemia

Vysis D7S486/CEP 7 FISH Probe Kit

Abbott Molecular Inc.

Acute Myeloid Leukemia

Vysis EGR1 FISH Probe Kit

Abbott Molecular Inc.

Acute Myeloid Leukemia

LeukoStrat CDx FLT3 Mutation Assay

INVIVOSCRIBE TECHNOLOGIES, INC

Acute Myeloid Leukemia

Abbott RealTime IDH2

ABBOTT MOLECULAR, INC.

Acute Myeloid Leukemia

Abbott RealTime IDH1

ABBOTT MOLECULAR, INC.

Acute Myeloid Leukemia or Myelodysplastic Syndrome

VYSIS EGR1 FISH PROBE KIT - SC (SPECIMEN CHARACTERIZATION

ABBOTT MOLECULAR, INC.

Aggressive Systemic Mastocytosi

KIT D816V ASSAY

ARUP LABARATORIES

Autosomal Recessive Carrier Screening

23ANDME PERSONAL GENOME SERVICE

23andMe

Source: U.S. FDA, June 2025

APAC Market Insights

Asia Pacific in the computational biology market is expected to emerge as the fastest-growing region, accounting for approximately 22.3% of the share during the forecast timeline. The market’s upliftment is highly attributed to the increased growth in the region’s biopharmaceutical industries, including India and China, which has further resulted in increased investments for the life science and healthcare sectors. According to the January 2025 Asia Development Organization, over 20 countries in the region constitute more than 20% risk of people suffering death due to chronic conditions. Besides, an early screening program was conducted in Mongolia, catering to 40% of the population as of 2023 to reduce stomach cancer, thus denoting a prolific opportunity for the market in the region.

The market in China is gaining increased traction, owing to the existence of administrative bodies approving drugs through biological research. According to the April 2025 NLM article, only 79 drugs were approved in the country over the past 11 years, and its international share of innovative drugs was 3% as of 2021. Besides, the National Medical Products Administration (NMPA) as of 2023 cleared 256 latest drugs through intense research, which in turn, is bolstering the market in the country. In addition, Class I innovative drug approvals reached 101 in the same year, along with the addition of 33, thereby denoting a 136% surge in the overall country.

The market in India is also gaining increased traction, owing to its implementation for aiding diabetes. According to a report published by the PIB in August 2023, the incidence of diabetes is 10.1 crores (1.1 million). However, to combat this, the Department of Health & Family Welfare, Government of India, provides financial and technical support to different states. Besides, the October 2022 Heliyon report stated that over the past 8 years household earnings in the country accounted for 5% to 25% of the share, along with an expenditure of USD 31 billion, thereby enhancing the market’s demand.

Percentage of Deaths in APAC Between 30 to 70 Years from CVD

Countries

Percentage

Afghanistan

32.7

Philippines

31.9

Myanmar

24.0

India

23.6

Georgia

22.1

Indonesia

21.9

Vietnam

20.1

Malaysia

19.9

Thailand

14.5

Sri Lanka

13.9

Source: Asian Development Blog Organization, June 2025

Europe Market Insights

Europe in the computational biology market is estimated to hold a considerable share of 27.5% by the end of the projected timeline. The market’s upliftment in the region depends on catering to severe challenges in healthcare, with increased focus on personalized medicine and drug delivery, along with managing complicated biological systems. Besides, as per the April 2025 NPJ report, there have been two initiatives, including the European Health Data Space (EHDS), which has covered 449 million of the population, as well as Germany’s forthcoming Health Data Lab, which has gathered data accessibility from 75 million insured patients, which is 90% of the country’s population. Therefore, these two strategies are effectively bolstering the market’s growth in the region.

The market in the UK is steadily gaining exposure, owing to the provision of healthcare budget. According to a report published by the UK Research and Innovation in March 2025, there has been an establishment of the Synthetic Biology for Growth programme by research councils in the country to allocate a budget of £102 million. This budget has been provided after achieving recommendations on biologic investment and research from the UK government. It comprises 4 main investment streams, including DNA synthesis, suitable training for students, synthetic biology seek fund, and multidisciplinary Synthetic Biology Research Centres (SBRCs).

The market in Germany is also growing due to an increase in the presence of doctors and hospitals. Based on this, the April 2025 NPJ report indicated that currently 430,000 doctors and 1,900 hospitals are focusing on the population, with a cost of over €1 billion per day, which accounts for 10% of the country’s gross domestic product (GDP). Besides, the 2025 Statistisches Bundesamt report denotes an increase in the overall health expenditure to €474.1 billion, accounting for €5,699 per inhabitant. In addition, the report also noted that there has been a surge in the country’s expenditure to €6,013, thereby denoting an upsurge in the market’s demand.

Computational Biology Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Key Computational Biology Market Players:

    The international market is extremely competitive, owing to the presence of notable players, including Thermo Fisher Scientific and Illumina, owing to their combined dominance in bioinformatics and sequencing. Besides, companies in Europe, such as Genedata and Dassault Systèmes, collectively specialize in AI-powered drug discovery, while U.S.-based firms, such as DNAnexus and Schrödinger, have focused on molecular modeling and cloud genomics. Meanwhile, AI collaborations, mergers and acquisitions, and cloud expansion are other tactical initiatives that are positively impacting the overall market’s growth internationally.

    Here is a list of key players operating in the global market:

    Company Name (Country)

    Industry Focus

    Market Share (2024)

    Thermo Fisher Scientific (U.S.)

    Bioinformatics software, NGS analysis, cloud solutions

    19.3%

    Illumina, Inc. (U.S.)

    AI-powered genomics & precision medicine platforms

    16.5%

    Dassault Systèmes BIOVIA (France)

    Molecular modeling & drug discovery software

    13.2%

    DNAnexus (U.S.)

    Cloud genomic data management & AI analytics

    9.6%

    Genedata AG (Switzerland)

    Pharma & agri-genomics software

    7.9%

    Schrödinger (U.S.)

    AI computational chemistry platforms

    xx%

    QIAGEN (Germany)

    NGS data analysis & clinical interpretation tools

    xx%

    Certara (U.S.)

    Biosimulation & PK/PD modeling software

    xx%

    Seven Bridges Genomics (U.S.)

    Biomedical data analysis platform

    xx%

    Benchling (U.S.)

    Cloud-based R&D informatics platform

    xx%

    Insilico Medicine (Hong Kong)

    AI-driven drug discovery platforms

    xx%

    DNASTAR (U.S.)

    Genomic sequence analysis software

    xx%

    Biomax Informatics AG (Germany)

    Knowledge management & omics analysis

    xx%

    SimBioSys (U.S.)

    Tumor modeling & surgical planning AI

    xx%

    Cyclica (Canada)

    AI-augmented drug discovery platform

    xx%

    Sources: Thermo Fisher, Illumina, Dassault, DNAnexus, Genedata, Schrödinger, McKinsey Pharma Tech Report, QIAGEN, Certara, Biopharma, Frost & Sullivan, Benchling Funding, Insilico Forbes Pharma AI, DNASTAR, GenomeWeb, Biomax European Biotech Journal, SimBioSys, Nature Digital Medicine, Cyclica, Eisai, Mitsubishi Investor Relations, RIKEN, CyberAgent Financials, Spiber

    Below are the areas covered for each company in the computational biology market:

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis

Recent Developments

  • In November 2024, NVIDIA announced the launch of the open-source NVIDIA BioNeMo Framework, which is suitable for international leaders, AI researchers, and academic pioneers to accelerate drug discovery and molecule design.
  • In October 2024, MiLaboratories stated the successful closing of Series A funding, which has been led by Madrid-based Kfund and backed by Speedinvest to unveil the next-generation Platforma.bio Software Development Kit (SDK) to transfer biologists and provide analytics from cutting-edge data.
  • Report ID: 3921
  • Published Date: Aug 14, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of the computational biology market was over USD 7.2 billion.

The market size for the computational biology market is projected to reach USD 22.8 billion by the end of 2035 expanding at a CAGR of 13.7% during the forecast period i.e., between 2026-2035.

The major players in the market are Seven Bridges Genomics, Benchling, Insilico Medicine, DNASTAR, and others.

In terms of the product segment, the software segment is anticipated to garner the largest market share of 42.7% by 2035 and display lucrative growth opportunities during 2026-2035.

The market in North America is projected to hold the largest market share of 42.2% by the end of 2035 and provide more business opportunities in the future.
GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.


Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos